Last Updated: November 16, 2026

Investigational Drug Information for Idraparinux

« Back to Dashboard


What is the development status for investigational drug Idraparinux?

Idraparinux is an investigational drug.

There have been 5 clinical trials for Idraparinux. The most recent clinical trial was a Phase 3 trial, which was initiated on November 1st 2003.

The most common disease conditions in clinical trials are Venous Thrombosis, Thrombosis, and Pulmonary Embolism. The leading clinical trial sponsors are Sanofi and [disabled in preview].

Recent Clinical Trials for Idraparinux
TitleSponsorPhase
Evaluation of Weekly Idrabiotaparinux Sodium Versus Oral Adjusted-dose Warfarin to Prevent Stroke and Systemic Thromboembolic Events in Patients With Atrial FibrillationSanofiPhase 3
Clinical Study Assessing Idrabiotaparinux Sodium Injections Once-weekly in Pulmonary Embolism Therapeutic ApproachSanofiPhase 3
Bioequipotency Study of Idrabiotaparinux and Idraparinux in Patients With Deep Venous Thrombosis of the Lower LimbsSanofiPhase 3

See all Idraparinux clinical trials

Clinical Trial Summary for Idraparinux

Top disease conditions for Idraparinux
Top clinical trial sponsors for Idraparinux

See all Idraparinux clinical trials

Idraparinux Development Update and Market Projection

Last updated: September 24, 2026

Idraparinux is a discontinued long-acting anticoagulant candidate that did not reach regulatory approval. Sanofi’s clinical program demonstrated once-weekly anticoagulation activity, but bleeding concerns in atrial fibrillation and the rapid expansion of oral direct anticoagulants eliminated the commercial rationale for further development. The current revenue forecast is effectively zero, and no active FDA approval, Orange Book listing, marketed product, or visible late-stage development program supports a conventional launch forecast.

What is the current development status of idraparinux?

Idraparinux is not an approved drug and does not have an active commercial development program in the public record.

The candidate is a synthetic pentasaccharide that indirectly inhibits factor Xa by binding antithrombin. Its pharmacology produced a terminal half-life of approximately 80 to 130 hours, allowing once-weekly subcutaneous administration. The same long exposure created a safety and reversibility problem when bleeding occurred.

Sanofi, formerly Sanofi-Aventis, advanced idraparinux in venous thromboembolism and atrial fibrillation. The principal development program included:

Program Indication Comparator Development result
AMADEUS Stroke prevention in atrial fibrillation Adjusted-dose warfarin Stopped early because of excess clinically relevant bleeding
Van Gogh-DVT Treatment of deep-vein thrombosis Standard anticoagulation Demonstrated activity but did not create a viable commercial product
Van Gogh-PE Treatment of pulmonary embolism Standard anticoagulation Development did not lead to approval
Idraparinux biotinylated, later called idrabiotaparinux Reversible long-acting anticoagulation Warfarin or standard therapy Development discontinued

The AMADEUS trial enrolled 5,457 patients with atrial fibrillation. Idraparinux reduced thromboembolic events relative to warfarin in the trial population, but major and clinically relevant nonmajor bleeding was higher. The study was stopped early because the benefit-risk balance was unfavorable, particularly in elderly patients and those with renal impairment (Bousser et al., 2008).

Why was idraparinux discontinued?

The primary failure point was the mismatch between long duration and poor control of anticoagulant effect.

Idraparinux had several clinical disadvantages:

  1. It was administered subcutaneously once weekly rather than orally.
  2. Its effect could persist for days after a bleeding event.
  3. It lacked a practical, established reversal strategy.
  4. Renal impairment increased exposure and complicated dosing.
  5. Atrial fibrillation patients often required indefinite treatment, magnifying cumulative bleeding exposure.
  6. Oral direct factor Xa inhibitors entered the market with more convenient dosing and better commercial positioning.

The biotinylated follow-on, idrabiotaparinux, was designed to permit neutralization by avidin. This addressed reversibility but did not solve the broader commercial and competitive problems. The program did not produce a marketed anticoagulant.

What clinical data support idraparinux?

Venous thromboembolism

The Van Gogh studies evaluated idraparinux as a once-weekly treatment for venous thromboembolism. Results showed that the drug could prevent recurrent thrombosis, but the program did not establish a regulatory path to approval.

The clinical opportunity was significant because treatment for deep-vein thrombosis and pulmonary embolism required prolonged anticoagulation. The product’s weekly administration could have reduced adherence burden. The benefit was offset by uncertainty around long-term bleeding management and the absence of a commercially acceptable antidote.

Atrial fibrillation

Atrial fibrillation was the largest potential indication but also exposed the candidate’s main weakness. The AMADEUS data showed that weekly dosing did not compensate for increased bleeding risk. This result sharply reduced the probability of approval in the most commercially attractive chronic indication.

Reversal strategy

Idrabiotaparinux incorporated a biotin group intended to allow reversal with avidin. The mechanism was scientifically differentiated, but a reversal technology does not automatically create a competitive product. The program still faced dosing, administration, safety, manufacturing, and market-access barriers.

What is the FDA regulatory status of idraparinux?

Idraparinux has no FDA approval and no FDA-approved label.

Regulatory item Status
FDA approval None
New Drug Application approval None publicly established
Biologics license application Not applicable
FDA-approved indication None
U.S. commercial product None
Orange Book listing None
U.S. generic approval pathway Not available
Reference listed drug None

Because idraparinux was never approved, it has no FDA regulatory exclusivity period and no approved labeling against which an abbreviated new drug application could be filed.

What is the Orange Book status of idraparinux?

Idraparinux has no Orange Book-listed patents or exclusivity entries tied to an approved product.

This distinction is important. Patents may have covered the compound, production methods, formulations, or therapeutic uses, but those patents do not create current Orange Book barriers because there is no approved reference product. A future developer would need to pursue a new drug application rather than rely on an ANDA pathway.

What patents protect idraparinux?

Patent protection historically focused on the synthetic pentasaccharide structure, stereochemistry, intermediates, manufacturing methods, pharmaceutical compositions, and anticoagulant uses. The relevant patent families were associated with Sanofi and predecessor entities, as well as earlier intellectual property covering synthetic heparin pentasaccharides.

The commercial relevance of those patents has declined for four reasons:

  • The original clinical program was discontinued.
  • Any early composition patents would generally be approaching or beyond ordinary 20-year terms, depending on priority dates and patent-term adjustments.
  • There is no approved product generating Orange Book patent linkage.
  • A new developer would still face substantial clinical and regulatory costs even if basic compound claims had expired.

A definitive patent-by-patent expiration analysis requires live review of U.S., European, Japanese, and other national registers. The public commercial record does not support treating idraparinux as an actively protected, launch-ready asset.

Are there Paragraph IV challenges involving idraparinux?

No conventional Paragraph IV litigation pathway is apparent.

Paragraph IV certifications apply to an ANDA referencing an approved drug listed in the Orange Book. Idraparinux has no approved reference product and no Orange Book listing. A party seeking to develop the compound today would more likely submit a full NDA supported by clinical and nonclinical data.

No significant public U.S. patent litigation involving an idraparinux generic launch is associated with an approved product. The absence of Paragraph IV litigation reflects the product’s regulatory status, not confirmation that every historical patent family has expired in every jurisdiction.

What formulation patents protect idraparinux?

Historical formulation and delivery protection would likely have focused on:

  • Subcutaneous injectable solutions;
  • Stabilized pentasaccharide compositions;
  • Single-dose or prefilled syringe presentations;
  • Weekly dosing regimens;
  • Biotinylated idraparinux formulations;
  • Combination or reversal approaches involving avidin.

These rights have limited current value without a development program. A new sponsor could potentially design around formulation claims, but the candidate’s route of administration and long half-life would remain embedded in the clinical risk profile.

What manufacturing and intellectual-property barriers remain?

Idraparinux is more difficult to manufacture than conventional small-molecule anticoagulants. It is a highly defined synthetic oligosaccharide with multiple stereochemical linkages and a demanding multistep manufacturing process. Commercial production would require:

  • Reproducible control of stereochemistry;
  • Tight impurity specifications;
  • Validated conjugation chemistry for idrabiotaparinux;
  • Scalable purification;
  • Sensitive analytical methods;
  • Demonstration of batch-to-batch structural consistency.

Manufacturing complexity would increase cost of goods and technical transfer risk. The candidate would also require renewed clinical work, including renal-impairment studies, bleeding-management studies, dose optimization, and a modern comparison against direct oral anticoagulants.

How does idraparinux compare with competing anticoagulants?

Product or class Route Dosing pattern Reversal position Commercial status
Idraparinux Subcutaneous Once weekly Historically limited; avidin strategy for idrabiotaparinux Discontinued, never approved
Warfarin Oral Usually once daily, monitored Vitamin K and prothrombin complex concentrate Generic and established
Rivaroxaban Oral Once or twice daily, indication-dependent Andexanet alfa or supportive strategies Approved and commercial
Apixaban Oral Twice daily Andexanet alfa or supportive strategies Approved and commercial
Edoxaban Oral Once daily Supportive and factor Xa reversal strategies Approved and commercial
Fondaparinux Subcutaneous Once daily No specific widely used antidote Approved and commercial
Low-molecular-weight heparins Subcutaneous Once or twice daily Partial protamine reversal Approved and commercial

Idraparinux’s once-weekly schedule was its main convenience advantage. That advantage was insufficient against oral administration, established reversal protocols, extensive clinical experience, and strong commercial uptake of direct oral anticoagulants.

What is the current patent litigation and settlement status?

No material active litigation or settlement involving an idraparinux launch is evident in the public regulatory record.

There is also no known settlement framework governing U.S. generic entry because no approved idraparinux product created an ANDA dispute. Historical licensing or collaboration arrangements associated with the compound did not result in a marketed medicine.

The most relevant commercial event was the termination of the development strategy rather than a patent settlement. Sanofi’s decision reflected clinical and competitive factors, not a publicly documented generic-entry settlement.

What companies are challenging idraparinux?

No company is publicly pursuing an idraparinux generic or biosimilar challenge.

Idraparinux is a synthetic oligosaccharide, not a biologic, so biosimilar competition is not the relevant pathway. A future entrant would face a full development program and could potentially pursue a 505(b)(2) strategy only if it could rely on an appropriate approved reference or sufficient published data. The absence of an approved reference product makes that route uncertain.

The active competitive threat comes from established anticoagulants rather than companies challenging idraparinux patents.

What is the market projection for idraparinux?

The base-case market projection is zero through 2030 because no sponsor is advancing the molecule toward approval and no commercial product exists.

Scenario Probability assessment 2030 revenue outlook
Base case: no redevelopment High $0
Limited regional revival for a specialty indication Low Below $50 million annually
Full redevelopment for venous thromboembolism Very low Potentially $100 million to $300 million, subject to successful trials
Broad atrial fibrillation launch Remote More than $500 million possible in theory, but commercially unlikely

The upside estimates are scenario values rather than consensus forecasts. A commercial revival would require a new sponsor, refreshed intellectual-property strategy, a reversal plan, modern comparator trials, and evidence that weekly subcutaneous dosing offers a clinically meaningful advantage over oral factor Xa inhibitors.

Revenue exposure

There is no current branded revenue exposure for Sanofi or another manufacturer. Any historical sales contribution was immaterial because idraparinux was never launched. For investors, the asset should be valued as a dormant or discontinued development program rather than as a near-term revenue opportunity.

Geographic coverage

Idraparinux did not obtain broad marketing authorization in the United States, European Union, Japan, or other major regulated markets. The absence of approval means there is no established geographic commercial footprint and no regional launch sequence to model.

What would be required for a new idraparinux launch?

A new sponsor would need to rebuild the program around current anticoagulation standards. The likely requirements would include:

  • A new regulatory development plan;
  • Pharmacokinetic and pharmacodynamic studies;
  • Renal and hepatic impairment studies;
  • Dose-selection work against current direct oral anticoagulants;
  • A validated bleeding-reversal strategy;
  • Phase 3 trials in venous thromboembolism or another defined population;
  • Commercial-scale synthetic manufacturing;
  • Updated patent filings covering formulation, dosing, reversal, or delivery.

The development timeline would likely exceed five years before potential approval, with substantial clinical and manufacturing expenditure. The candidate’s historical data could support background knowledge but would not remove the need for contemporary comparative evidence.

Key Takeaways

  • Idraparinux is a discontinued, never-approved anticoagulant candidate.
  • Sanofi’s AMADEUS trial identified excess bleeding as the central clinical problem.
  • Idrabiotaparinux attempted to improve reversibility but did not reach commercialization.
  • Idraparinux has no FDA approval, Orange Book listing, regulatory exclusivity, or generic Paragraph IV market.
  • No active biosimilar or generic challenge is relevant.
  • Historical patents may have covered compound, manufacturing, formulation, and use claims, but the active commercial value of the estate is limited.
  • The base-case market forecast is zero through 2030.
  • Any revival would require a new sponsor, new clinical evidence, a credible reversal strategy, and a clear advantage over oral direct factor Xa inhibitors.

FAQs

Is idraparinux still being developed?

No active late-stage development program is publicly established. The original program and the idrabiotaparinux follow-on were discontinued.

Did idraparinux receive FDA approval?

No. Idraparinux never received FDA approval and has no approved U.S. indication.

Can a generic company launch idraparinux?

Not through a standard ANDA referencing an approved idraparinux product. A new sponsor would likely need an NDA-level development strategy.

Was idraparinux more effective than warfarin?

It showed anticoagulant efficacy in clinical trials, but the AMADEUS study found excess bleeding that made the overall benefit-risk profile unacceptable for atrial fibrillation.

Is idraparinux a biologic eligible for biosimilar competition?

No. Idraparinux is a synthetic pentasaccharide. Biosimilar legislation is not the principal regulatory framework for this molecule.

References

  1. Bousser, M. G., Bouthier, J., Büller, H. R., Cohen, A. T., Crijns, H., Davidson, B. L., et al. (2008). Comparison of idraparinux with vitamin K antagonists for prevention of thromboembolism in patients with atrial fibrillation: A randomised, open-label, non-inferiority trial. The Lancet, 371(9609), 315-321.

  2. Büller, H. R., Cohen, A. T., Davidson, B., Decousus, H., Gallus, A. S., Gent, M., et al. (2007). Idraparinux versus standard therapy for venous thromboembolic disease. The New England Journal of Medicine, 357(11), 1094-1104.

  3. ClinicalTrials.gov. (n.d.). A study of idraparinux versus warfarin in patients with atrial fibrillation: AMADEUS. U.S. National Library of Medicine.

  4. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations. Center for Drug Evaluation and Research.

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.